Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic

摘要

Allogeneic transplant for myeloma remains controversial at best. We have reviewed more than 20 years of experience at Mayo Clinic to report our outcomes in a mostly relapsed/refractory population in a nontandem setting. Hardly justifiable as front-line, the long-term survival rate was 20% for the end-of-the-line option.